SākumlapaAVXT • OTCMKTS
add
AVAX Technologies Inc
Slēgšanas kurss
0,000010 $
Tirgus kapitalizāc.
1,43 tūkst. USD
Vid. apjoms
2,26 tūkst.
P/E koeficients
-
Ienākumi no dividendēm
-
Galvenā birža
OTCMKTS
Tirgus ziņas
Par
Avax Technologies, Inc. is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate of 44% and response rate of 35%. Wikipedia
Dibināšanas datums
1990
Galvenais birojs
Tīmekļa vietne
Darbinieki
29